Clinical Trial Update: Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluates a combination of interleukin-2, vinblastine, and GM-CSF for metastatic renal cell carcinoma; the current trial status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Interleukin-2 (interleukin-2)
• Vinblastine (vinblastine)

Snippet

Sponsor: Hope Cancer Institute, Inc. | Conditions: Kidney Cancer | Phase 2 | Status: UNKNOWN